Friday, September 04, 2020 8:16:09 PM
On the other hand, I think the recent data from Mayo are much more promising than the market seems to think, especially in light of the changed endpoint.
I bought some shares before the 08/03 conference call but had serious doubts w.r.t. the endpoint and sample size changes and about the the whispers of substantial share dilution in the not-too-distant future. I kept my shares, though, on the implicit "recommendation" the FDA gave by selecting lenz for BET. I still think it is a good bet for covid-19 success, but maybe I should have waited until next week to buy!
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM